Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients

This is a multi-center, phase I/II study to determine the efficacy and safety of CRC01 in adult patients with relapsed or refractory large B-cell lymphoma and B-cell Acute Lymphoblastic Leukemia.

Trial Details

NCT ID
NCT04836507
Phase
PHASE1 / PHASE2
Sponsor
Curocell Inc.
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • CRC01
  • Fludarabine
  • Cyclophosphamide
Locations (sample)
  • Seoul, South Korea|37.566,126.9784
  • Seoul, South Korea|37.566,126.9784

Key Eligibility Criteria

  • ≥ 19 years of age and provided written informed consent
  • Histologically confirmed following large B-cell lymphomas according to the World Health Organization classification 2017
  • Diffuse large B-cell lymphoma, not otherwise specified Including Large cell transformation from follicular lymphoma (Transformed follicular lymphoma)
  • High-grade B-cell lymphoma, not otherwise specified

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →